# Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

> **NCT04310176** · PHASE2 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 200 (estimated)

## Conditions studied

- Ras-mutated Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** mFOLFOX6 regimen
- **DRUG:** mOXXEL regimen
- **DRUG:** Valproic acid
- **DRUG:** Capecitabine
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT04310176
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-24
- **Primary completion:** 2023-12
- **Final completion:** 2024-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04310176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04310176, "Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04310176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*